S104 Cost-effectiveness of triple therapy with budesonide/glycopyrronium/formoterol fumarate versus dual therapies in moderate-to-very severe COPD in the United Kingdom: analysis based on the KRONOS study

Authors :: N. Brighton
A. Walker
Ulf Holmgren
John Haughney
E. De Nigris
C. Treharne
Source :: Ease that wheeze: managing risk in COPD.
Publication Year :: 2021
Publisher :: BMJ Publishing Group Ltd and British Thoracic Society, 2021.

Subjects :: Budesonide
medicine.medical_specialty
Cost effectiveness
business.industry
Internal medicine
medicine
Formoterol Fumarate
Severe copd
business
medicine.drug

Tools